Treatment of Cellulitis in Patients with Chronic Lymphocytic Leukemia (CLL)

Pathophysiology and Risk Factors

CLL patients develop severe immune defects during the course of their disease, making infections a common complication, according to the European Society for Medical Oncology 1, 2
Immune dysfunction in CLL increases susceptibility to bacterial infections, particularly skin infections like cellulitis, as reported by the American Society of Clinical Oncology 3

Patient's prior antibiotic exposure and allergies should be considered when selecting antibiotics, as recommended by the National Comprehensive Cancer Network 2

For CLL patients with compromised immunity, a full 10-day course of antibiotic therapy is generally recommended to ensure complete resolution and prevent recurrence, according to the European Society for Medical Oncology 2

For severe cellulitis or cases with systemic symptoms, hospitalization for intravenous antibiotics should be considered, as recommended by the American Society of Clinical Oncology 2
Monitor closely for signs of sepsis or disease progression, according to the European Society for Medical Oncology 1
Evaluate for potential complications such as bacteremia, as reported by the American Society of Clinical Oncology 3

Antibiotic prophylaxis should be considered in CLL patients with recurrent infections, very high risk of developing infections, or patients receiving treatments that further compromise immunity, as recommended by the National Comprehensive Cancer Network 2, 4
Pneumococcal and seasonal influenza vaccinations are recommended for CLL patients, according to the Centers for Disease Control and Prevention 4, 5

Patients with CLL on specific treatments may have increased risk of fungal infections, especially when corticosteroids are used concomitantly, as reported by the American Society of Clinical Oncology 4
For patients with severe hypogammaglobulinemia and repeated infections, consider intravenous immunoglobulin replacement therapy, as recommended by the European Society for Medical Oncology 4, 5
Be vigilant for transformation to more aggressive disease forms, which can present with worsening infections, according to the American Society of Clinical Oncology 6